The Consortium for TB Biomarkers (CTB2) is composed of three strong organizations central to TB clinical drug development, each having plans to conduct late stage TB studies; for a list of the individuals comprising CTB2 Executive Membership, see CTB2 Executive Members:
WHO WE ARE
The TB Alliance's mission is to discover and develop better, faster-acting, and affordable drugs to fight tuberculosis.
Before the TB Alliance was established, there were no clinical-stage TB drug candidates being developed, let alone realistic hope for novel TB drug regimens. Today, working with a broad range of public and private stakeholders, including pharmaceutical companies, universities, and other research laboratories around the world, the TB Alliance is leading the advancement of the most comprehensive portfolio of TB drug candidates in history. From this global network, the TB Alliance leverages the most promising science to advance new TB drug regimens that are needed to fight this pandemic.
The mission of the AIDS Clinical Trials Group (ACTG) Network is to develop and conduct scientifically rigorous translational research and clinical trials to:
Investigate the viral and immune pathogenesis of HIV-1 infection and its complications;
Evaluate novel drugs and strategies for treating HIV-1 infection;
Evaluate interventions and strategies to treat and prevent HIV-related co-infections and co-morbidity;
Publish and disseminate results to improve care, and reduce or eliminate morbidity and mortality associated with HIV-1 infection and its complications.
The TBTC is comprised of clinical investigators from academic medical centers and health departments in North America and internationally, and Veterans Affairs (VA) medical centers in the United States of America, working closely with staff from the CDC's Division of Tuberculosis Elimination (DTBE).